In recent trading session, Hepion Pharmaceuticals Inc (NASDAQ:HEPA) saw 1.57 million shares changing hands at last check today with its beta currently measuring 1.59. Company’s recent per share price level of $0.18 trading at -$0.01 or -6.22% at last check today assigns it a market valuation of $1.88M. That most recent trading price of HEPA’s stock is at a discount of -1750.0% from its 52-week high price of $3.33 and is indicating a premium of 33.33% from its 52-week low price of $0.12.
For Hepion Pharmaceuticals Inc (HEPA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information
Upright in the red during last session for losing -6.22%, in the last five days HEPA remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $0.18 price level, adding 12.2% to its value on the day. Hepion Pharmaceuticals Inc’s shares saw a change of -62.50% in year-to-date performance and have moved -12.98% in past 5-day. Hepion Pharmaceuticals Inc (NASDAQ:HEPA) showed a performance of 30.59% in past 30-days.
Wall Street analysts have assigned a consensus price target of 70 to the stock, which implies a rise of 99.74% to its recent value today. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 70. It follows that stock’s current price would drop -38788.89% in reaching the projected high whereas dropping to the targeted low would mean a loss of -38788.89% for stock’s current value.
Hepion Pharmaceuticals Inc (HEPA) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 63.67% during past 5 years.
On the other hand, Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 48.91 shares of worth $8612.0 or 0.70% of the total outstanding shares. The later fund manager was in possession of 40.67 shares on Sep 30, 2024, making its stake of worth around $7162.0 in the company or a holder of 0.58% of company’s stock.
